- Q1 2024 Seres Therapeutics Inc Earnings Call TranscriptMay 08, 2024$0.7494 (-32.49%)Earnings
- Q4 2023 Seres Therapeutics Inc Earnings Call TranscriptMar 05, 2024$1.06 (-7.02%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2023$0.9324 (-35.25%)Earnings
- Seres Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Seres Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Seres Therapeutics Inc Earnings Call TranscriptAug 08, 2023$4.29 (-6.94%)Earnings
- Seres Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Seres Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Seres Therapeutics Inc Earnings Call TranscriptMay 09, 2023$5.57 (+0.18%)Earnings
- Seres Therapeutics Inc To Discuss SER-109 Approval Call TranscriptApr 27, 2023
- Q4 2022 Seres Therapeutics Inc Earnings Call TranscriptMar 07, 2023$5.4 (-1.64%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Seres Therapeutics Inc To Discuss Ser-109 Commercial Strategy Call TranscriptDec 08, 2022
- Q3 2022 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2022$8.19 (-9.50%)Earnings
- Q2 2022 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2022$4.45 (+8.54%)Earnings
- Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call TranscriptJun 07, 2022
- Q1 2022 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2022$4.72 (-2.48%)Earnings
- Q4 2021 Seres Therapeutics Inc Earnings Call TranscriptMar 01, 2022$7.4 (-7.56%)Earnings
- Seres Therapeutics Inc To Highlight Opportunities For Microbiome Therapeutics In Infection Protection Call TranscriptJan 31, 2022
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Seres Therapeutics Inc Earnings Call TranscriptNov 10, 2021$8.27 (+20.38%)Earnings
- Q2 2021 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2021$6.96 (-1.00%)Earnings
- Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call TranscriptJul 22, 2021
- Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call TranscriptJul 01, 2021
- Seres Therapeutics Inc SER-287 Clinical Data Update Call TranscriptJun 21, 2021
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2021$21.48 (+5.55%)Earnings
- Q4 2020 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2021$19.62 (-4.85%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Seres Therapeutics Inc Earnings Call TranscriptNov 09, 2020$33.24 (-3.90%)Earnings
- Seres Therapeutics, Inc. - Special Call TranscriptAug 10, 2020
- Seres Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- Seres Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Seres Therapeutics Inc Earnings Call TranscriptMay 07, 2020$4.27 (+12.37%)Earnings
- Q4 2019 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2020$3.23 (+2.87%)Earnings
- Q3 2019 Seres Therapeutics Inc Earnings Call TranscriptNov 05, 2019$4.06 (+6.84%)Earnings
- Q2 2019 Seres Therapeutics Inc Earnings Call TranscriptAug 06, 2019$2.29 (-6.15%)Earnings
- Q1 2019 Seres Therapeutics Inc Earnings Call TranscriptMay 02, 2019$5.35 (-12.44%)Earnings
- Q4 2018 Seres Therapeutics Inc Earnings Call TranscriptMar 06, 2019$6.12 (-3.62%)Earnings
Q4 2018 Seres Therapeutics Inc Earnings Call Transcript
Good morning, and welcome to the Seres Therapeutics Conference Call. As a reminder, this conference is being recorded and will be available on Seres' website for replay. And I would now like to introduce your host for today's call, Dr. Carlo Tanzi, Vice President, Investor Relations and Corporate Communications. Please go ahead.
Thank you, Josh, and good morning. A press release with the company's fourth quarter and full year 2018 financial results and a business update became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors and Media section of the company's website.
I'd like to remind you that we'll be making forward-looking statements relating to our development plans; the impact of our recent corporate changes; the timing of the ECOSPOR III study and its ability to support approval; the promise and potential impact of any of our microbiome therapeutics or clinical trial data; the expected regulatory requirements for the SER-287 Phase
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)